Serum Human epididymal protein 4 as a predictor of adverse events in acute ischemic stroke patients receiving antiplatelet therapy Authors: Na Liu, Ning Bao, Guang Liu, Xiaowei Luo Published: 2026 ABSTRACT AbstractBackgroundAcute kidney injury (AKI) frequently develops in certain patients with acute ischemic stroke (AIS) and often indicates a poor prognosis. However, the relationship between serum human epididymal protein 4 (HE4), a newly recognized biomarker of renal injury, and adverse outcomes in AIS patients remains unclear.AimThis study aimed to investigate the prognostic value of admission serum HE4 levels for predicting unfavorable outcomes in AIS patients undergoing antiplatelet therapy.MethodsWe conducted a cohort study involving 144 consecutive adult patients admitted for AIS who received antiplatelet treatment. Blood samples were collected after admission to measure serum HE4 concentrations.ResultsSerum HE4 levels were markedly elevated in AIS patients on antiplatelet therapy compared with healthy controls (116.4 ± 24.8 pmol/L vs. 25.3 ± 9.8 pmol/L). Kaplan–Meier analysis revealed that higher HE4 levels were associated with an increased incidence of cardiovascular events and/or recurrent stroke. Multivariate Cox regression analysis indicated that elevated HE4 concentrations independently predicted a higher risk of cardiovascular events (HR = 3.02; 95% CI: 1.51–6.29; P = 0.01) and stroke recurrence (HR = 3.81; 95% CI: 1.64–6.63; P < 0.01).ConclusionsElevated serum HE4 levels are significantly associated with a heightened risk of cardiovascular events and recurrent stroke in AIS patients receiving antiplatelet therapy, suggesting that HE4 may serve as a potential biomarker for predicting adverse outcomes in this population.Keywords: HE4, Stroke, Adverse outcomes, Death, Antiplatelet therapy Introduction Acute kidney injury (AKI) is a common complication in patients with acute stroke, driven by the brain–kidney interaction, with reported incidence rates ranging from 10.28% to 35.30% and reaching as high as 51.90% in critically ill individuals [1–3]. Previous evidence indicates that the occurrence of AKI significantly increases the rates of disability and mortality among stroke patients [4–6]. AKI is a preventable clinical syndrome, and timely monitoring and intervention can substantially reduce adverse events in this population [7, 8]. Post-stroke AKI is primarily mediated by the “neuro-humoral-inflammatory” axis, reflecting a complex bidirectional crosstalk between the brain and kidneys that results in remote organ damage. The core pathophysiology involves hemodynamic disturbances, excessive neuroendocrine activation, and systemic inflammatory responses, which are independent of antiplatelet agents [7, 8]. Therefore, early risk assessment is crucial to prevent AKI progression. However, evidence regarding specific AKI screening tools for stroke patients remains limited. Identifying novel biomarkers or establishing risk prediction models for post-stroke AKI could enable early and accurate identification of high-risk individuals. Human epididymal protein 4 (HE4) is well known as a tumor biomarker, particularly valuable for monitoring the progression and recurrence of ovarian cancer [9]. Recent studies have revealed its high expression in renal tissue [10, 11]. Serum HE4 levels are significantly elevated in patients with impaired renal function and have been linked to the progression of chronic kidney disease (CKD). Even in early-stage CKD, increased serum HE4 concentrations suggest its potential as a biomarker of early renal impairment [12, 13]. Given the limited evidence on the association between serum HE4 and early or acute kidney injury in acute ischemic stroke (AIS) patients, the present study was designed to assess whether HE4 could serve as a predictive biomarker for adverse outcomes in AIS patients receiving antiplatelet therapy. Materials and methods Patients Consecutive sampling was used to enroll AIS patients on antiplatelet therapy who were hospitalized at the People’s Hospital Affiliated to Chongqing Three Gorges Medical College between January 2019 and December 2021 (N = 144). None of the included patients received thrombolysis or endovascular interventions, as most were beyond the time window for thrombolysis, had contraindications, or had families who declined such treatment. For these stroke patients undergoing standard care, antiplatelet therapy is the cornerstone of secondary prevention. Except for those with atrial fibrillation-related cerebral infarction who received anticoagulation, the majority received a loading dose (aspirin 300 mg and clopidogrel 300 mg on day 1, followed by aspirin 100 mg and clopidogrel 70 mg from day 2 to day 21). After three weeks of dual antiplatelet therapy, patients continued on daily aspirin 100 mg or clopidogrel 70 mg. Inclusion criteria were: (1) age ≥ 18 years; (2) diagnosis of AIS confirmed by cranial CT and/or MRI according to electronic medical records [14]. Exclusion criteria were: (1) diagnosis of renal insufficiency within one week before admission; (2) non-adherence to prescribed antiplatelet therapy or incomplete medical records; (3) concomitant severe cardiopulmonary dysfunction, malignancy, or other serious chronic diseases. AKI was defined according to the KDIGO 2021 Guideline for the Management of Glomerular Diseases [15], meeting any of the following: (1) an absolute increase in serum creatinine ≥ 26.5 μmol/L (0.3 mg/dL) within 48 h; (2) a ≥ 1.5-fold increase in serum creatinine from baseline within 7 days; (3) urine output < 0.5 mL·kg⁻1·h⁻1 for > 6 h. Clinical information was extracted from the electronic medical record system by two trained researchers, and a third researcher verified the completeness, authenticity, and accuracy of the data. To preliminarily characterize HE4 level changes in stroke patients, an age- and sex-matched healthy control group was selected. Healthy individuals were defined as those without respiratory diseases, cardiovascular diseases, tumors, or other chronic conditions identified during physical examinations. Laboratory test Fasting venous blood from the upper limb was collected on the first morning after admission. Samples were centrifuged at 3,500 rpm for 15 min, and the serum was stored at –80 °C for subsequent HE4 measurement. Kits for detecting serum HE4, creatinine, urea nitrogen, and uric acid were purchased from Beijing Dingguo Changsheng Biotechnology Co., Ltd. Serum HE4 levels were measured using an electrochemiluminescence immunoassay. Other routine parameters were analyzed using a Beckman Coulter AU5800 chemistry analyzer (Beckman Coulter Inc.). Outcome events All stroke patients were followed up every three months via telephone or outpatient visits. Outcome events comprised cardiovascular events or stroke recurrence. Cardiovascular events were defined as acute myocardial infarction, acute heart failure, or sudden cardiac death, diagnosed by consensus of two attending cardiologists according to relevant guidelines [16]. Stroke recurrence was defined as a new acute ischemic event at the original or a different site, confirmed by two attending neurologists using established criteria [17]. The follow-up period was three years after admission, and events occurring during this period were considered endpoints. Statistical analysis All statistical analyses were performed using SPSS version 26.0. Normality of continuous variables was assessed using the Kolmogorov–Smirnov test. Continuous data are expressed as mean ± standard deviation (SD). Kaplan–Meier curves with log-rank tests were used to evaluate the association between serum HE4 levels and the risk of clinical events. Multivariable Cox regression models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for covariates. The crude model included no adjustments; Model 1 adjusted for age, sex, and comorbidities (hypertension, diabetes, coronary heart disease, CKD, chronic obstructive pulmonary disease, and others); Model 2 further adjusted for age, sex, comorbidities, estimated glomerular filtration rate (eGFR), and medications (antiplatelet drugs, lipid-lowering agents, anticoagulants, antihypertensives, and hypoglycemic agents). The diagnostic performance of serum HE4 for clinical events was assessed using receiver operating characteristic (ROC) curves. A two-sided P value < 0.05 was considered statistically significant. Results Baseline characteristics Serum HE4 levels were measured in 144 AIS patients receiving antiplatelet therapy and 138 healthy non-stroke individuals (Table 1). Circulating HE4 concentrations were significantly higher in stroke patients than in healthy controls (116.4 ± 24.8 pmol/L vs. 25.3 ± 9.8 pmol/L). Among the stroke patients (Table 2), mean age was 64.7 ± 10.2 years, and 50 (86.2%) were male. AKI on admission was present in 31.1% of stroke patients. Comorbidities included hypertension (82, 56.9%), diabetes (64, 44.4%), coronary heart disease (19, 13.2%), CKD (10, 6.9%), chronic obstructive pulmonary disease (9, 6.3%), and others (5, 3.5%). During follow-up, cardiovascular events occurred in 15 patients (10.4%) and recurrent stroke in 31 patients (21.5%). Importantly, Kaplan–Meier analysis showed that stroke patients with higher serum HE4 levels tended to have higher rates of cardiovascular events (P < 0.05; Fig. 1A) and recurrent stroke (P < 0.05; Fig. 1B). Table 1Serum HE4 levels in patients with acute ischemic stroke with antiplatelet therapyVariablesPatients with acute ischemic stroke (N = 144)Healthy controls(N = 138)P valueAge (years)64.7 ± 10.265.3 ± 11.80.557Male, n (%)92 (63.9)89 (64.5)0,638Serum HE4 (pmol/L)116.4 ± 24.825.3 ± 9.8 < 0.01HE4 Human epididymis protein 4 Serum HE4 levels in patients with acute ischemic stroke with antiplatelet therapy HE4 Human epididymis protein 4 Table 2Baseline characteristics among patients with acute ischemic stroke (N = 144)VariablesMean ± standard deviation/N (%)Age, years64.7 ± 10.2Male, n (%)92 (63.9)AKI, n (%)45 (31.3)Comorbidities Hypertension, n (%)82 (56.9) Diabetes, n (%)64 (44.4) Coronary heart disease, n (%)19 (13.2) Chronic kidney disease, n (%)10 (6.9) Chronic obstructive pulmonary disease, n (%)9 (6.3) Others, n (%)5 (3.5)Blood parameters Serum HE4 (pmol/L)116.4 ± 24.8 eGFR (mL/min/1.73 m2)57.8 ± 7.8 Albumin (g/L)45.4 ± 6.2 BNP (pg/mL)102.4 ± 15.8 Hemoglobin (g/L)118 ± 16.4 White blood cells (109/L)8.1 ± 2.4 Platelet count (109/L)165.2 ± 24.9 HbA1c (%)5.6 ± 1.1 Low-density lipoprotein (mmol/L)3.9 ± 1.5 Triglyceride (mmol/L)1.7 ± 0.5 High-density lipoprotein (mmol/L)1.4 ± 0.6 C-reactive protein (mg/L)8.5 ± 1.9Medications Antiplatelet drugs, n (%)140 (97.2) Lipid lowering drugs, n (%)144 (100.0) Anticoagulants, n (%)10 (6.9) Antihypertensive drugs, n (%)78 (54.2) Hypoglycemic drugs, n (%)56 (38.9)Outcome events Cardiovascular events, n (%)15 (10.4) Recurrent stroke, n (%)31 (21.5)HE4 Human epididymis protein 4, AKI Acute kidney injury, eGFR estimated glomerular filtration rate Baseline characteristics among patients with acute ischemic stroke (N = 144) HE4 Human epididymis protein 4, AKI Acute kidney injury, eGFR estimated glomerular filtration rate Cumulative curve analysis for adverse outcomes among patients after acute ischemic stroke Cox analysis for outcome events Multivariate Cox analysis was performed to evaluate the association between serum HE4 concentrations and outcome events. In the crude model (Table 3), HE4 was positively associated with cardiovascular events (HR = 3.7; 95% CI: 1.56–7.12; P < 0.01) and recurrent stroke (HR = 4.6; 95% CI: 1.72–7.94; P < 0.01). After full adjustment in Model 2 [(including age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others), eGFR and medications (antiplatelet drugs, lipid lowering drugs, anticoagulants, antihypertensive drugs and hypoglycemic drugs)], elevated HE4 remained independently associated with a higher risk of cardiovascular events (HR = 3.02; 95% CI: 1.51–6.29; P = 0.01) and recurrent stroke (HR = 3.81; 95% CI: 1.64–6.63; P < 0.01). Sensitivity analysis indicated that AKI did not significantly modify the association between serum HE4 and outcome events (Table 4). Table 3Cox analysis for the association of serum HE4 with outcome eventsSerum HE4Outcome eventsCardiovascular eventsRecurrent strokeCrude Model3.7 (1.56 to 7.12), < 0.014.6 (1.72 to 7.94), < 0.01Model 13.2 (1.52 to 6.35), < 0.014.0 (1.69 to 7.06), < 0.01Model 23.02 (1.51 to 6.29), 0.013.81 (1.64 to 6.63), < 0.01Crude Model: Adjusted for noneModel 1: Adjusted for age, gender, and comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others)Model 2: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others), eGFR and medications (antiplatelet drugs, lipid lowering drugs, anticoagulants, antihypertensive drugs and hypoglycemic drugs)HE4 Human epididymis protein 4, eGFR estimated glomerular filtration rate Cox analysis for the association of serum HE4 with outcome events Crude Model: Adjusted for none Model 1: Adjusted for age, gender, and comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others) Model 2: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others), eGFR and medications (antiplatelet drugs, lipid lowering drugs, anticoagulants, antihypertensive drugs and hypoglycemic drugs) HE4 Human epididymis protein 4, eGFR estimated glomerular filtration rate Table 4Sensitive analysis for the association of serum HE4 with outcome eventsSerum HE4Outcome eventsCardiovascular eventsRecurrent strokeCrude Model3.6 (1.53 to 7.05), < 0.014.5 (1.70 to 7.63), < 0.01Model 13.0 (1.51 to 6.39), < 0.013.7 (1.63 to 6.94), < 0.01Model 22.93 (1.49 to 6.16), 0.023.6 (1.62 to 6.61), < 0.01Crude Model: Adjusted for AKIModel 1: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others) and AKIModel 2: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others), eGFR, medications (antiplatelet drugs, lipid lowering drugs, anticoagulants, antihypertensive drugs and hypoglycemic drugs) and AKIHE4 Human epididymis protein 4, AKI Acute kidney injury, eGFR estimated glomerular filtration rate Sensitive analysis for the association of serum HE4 with outcome events Crude Model: Adjusted for AKI Model 1: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others) and AKI Model 2: Adjusted for age, gender, comorbidities (hypertension, diabetes, coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and others), eGFR, medications (antiplatelet drugs, lipid lowering drugs, anticoagulants, antihypertensive drugs and hypoglycemic drugs) and AKI HE4 Human epididymis protein 4, AKI Acute kidney injury, eGFR estimated glomerular filtration rate ROC curve analysis for detecting composite event As shown in Table 5, serum HE4 demonstrated better diagnostic performance for composite events (cardiovascular events plus recurrent stroke) than eGFR, a conventional AKI marker, in AIS patients on antiplatelet therapy. The area under the curve (AUC) values were 0.753 for HE4 and 0.719 for eGFR. Notably, the combined model of HE4 and eGFR yielded an AUC of 0.845. These results suggest that serum HE4 may serve as a novel biomarker for prognosis assessment in post-stroke patients. Table 5ROC curve analysis for detecting composite eventExposureComposite eventAUCSensitivity (%)Specificity (%)HE40.75372.69%67.83%eGFR0.71971.85%66.84%HE4 + eGFR0.84584.73%78.96%HE4 Human epididymis protein 4, eGFR estimated glomerular filtration rate ROC curve analysis for detecting composite event HE4 Human epididymis protein 4, eGFR estimated glomerular filtration rate Discussion Existing evidence indicates that AKI is a significant risk factor for mortality in intensive care unit (ICU) patients and other seriously ill populations [16, 17]. The high mortality risk is mechanistically explained by the adverse effects of AKI on the heart, brain, liver, lungs, and gastrointestinal tract [18, 19]. AKI can also increase the likelihood of CKD, and cardiovascular complications such as myocardial infarction, ultimately leading to heart failure and long-term functional impairment beyond the acute phase [19]. However, data on stroke recovery following AKI in post-acute stroke patients are scarce [20], and the long-term adverse outcomes after AKI in this population remain largely unknown. HE4 is encoded by the WFDC2 gene and belongs to the whey acidic protein (WAP) domain-containing family. It consists of five exons and four introns, encoding a small secreted glycoprotein [9]. HE4 is highly expressed in ovarian cancer and fibrotic diseases, participates in extracellular matrix remodeling, and serves as an important tumor and fibrosis biomarker [9–13]. To our knowledge, this is the first study to demonstrate that serum HE4, as a marker of early renal dysfunction [10–13], is positively associated with an increased risk of cardiovascular events and stroke recurrence in AIS patients receiving antiplatelet therapy. This finding aligns with previous reports that poor renal function portends a higher risk of cardiovascular disease and related mortality in patients with renal insufficiency from various causes [21]. Also, numerous clinical studies have shown that HE4 is markedly upregulated during renal fibrosis, and its serum levels in CKD or renal dysfunction patients are negatively correlated with worse glomerular filtration rate [12, 13]. These observations indicate that HE4, as a biomarker of early kidney injury, is indeed a potential indicator of adverse events in post-stroke patients. Nevertheless, our sensitivity analysis revealed that AKI did not significantly alter the independent association between serum HE4 and cardiovascular events or recurrent stroke, suggesting that HE4 may also influence stroke prognosis through other pathways given its biological pleiotropy. Consistent with existing literature, our results support the notion that elevated serum HE4 could be an important biomarker (the renal pathway) reflecting cardiovascular risk in these stroke patients. Future validation in larger, multicenter cohorts is still warranted. Interestingly, the HE4 sequence shares similarity with proteinase inhibitors implicated in cardiac fibrosis [22, 23]. For example, a prior study demonstrated that HE4 is involved in myocardial fibrosis by activating cardiac fibroblasts and can predict progressive fibrosis and cardiovascular events in patients with dilated cardiomyopathy [24]. Another clinical investigation showed that elevated serum HE4 levels predict a higher risk of cardiovascular death and heart failure readmission in individuals with ischemic heart disease [25]. A recent study also reported that serum HE4 levels are positively associated with an increased likelihood of heart failure in CKD patients [26]. These findings may further explain why, beyond the renal pathway, HE4 itself may directly contribute to the progression of cardiovascular and cerebrovascular diseases in post-stroke patients. Collectively, these results suggest that HE4 elevation may be also a causal factor in the development of adverse cardiovascular events. Several limitations should be acknowledged. The most significant drawback is the small sample size from a single center, which limits generalizability. Future multicenter studies with larger cohorts are necessary. When considering serum HE4 as an indicator for adverse events in AIS patients on antiplatelet therapy, the potential impact of cancers, particularly common tumors such as ovarian and lung cancer, should be emphasized [9]. In this study, patients with a clear history of malignancy were excluded, enabling a more accurate estimation of the relationship between serum HE4 and outcome events. Moreover, because serum HE4 levels are also elevated in other chronic conditions, including inflammatory diseases and CKD [27–29], further research is required to refine the extrapolation of HE4’s predictive value in post-stroke patients. Additionally, although multivariate adjustments were performed, some residual confounders (detailed medication use and dynamic renal function changes) may not have been fully addressed, potentially introducing some uncertainty into the robustness of our findings. Conclusion Our results demonstrate that serum HE4, a fibrosis-related biomarker of renal function, can be considered a predictor of cardiovascular events and/or recurrent stroke in AIS patients receiving antiplatelet therapy. However, its generalizability requires further confirmation, particularly in patients with coexisting malignancies. Acknowledgments Author statement This manuscript has been read and approved by all authors, each of whom believes that the manuscript represents honest work. Authors’ contributions Na Liu completed the original manuscript text; Ning Bao and Guang Liu completed data validation; Xiaowei Luo revised the final manuscript. All authors reviewed the manuscript. Funding The study was not supported by fund. Data availability Sequence data that support the findings of this study was belonging to our research group. Declarations Ethics approval and consent to participate This study was approved by the Human Research Ethics Committee of the People’s Hospital Affiliated to Chongqing Three Gorges Medical College in accordance with the Declaration of Helsinki, and written informed consent was obtained from all participants. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Sequence data that support the findings of this study was belonging to our research group.